IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 23, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2026

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

IPH5201 + durvalumab + standard chemotherapy

"Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab."

Trial Locations (30)

8582

RECRUITING

Veszprem County Pulmonology Institute, Farkasgyepű

9024

RECRUITING

Petz Aladar University Teaching Hospital, Department of Pulmonology, Győr

11042

NOT_YET_RECRUITING

Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics, Lake Success

11526

RECRUITING

Henry Dunant Hospital Center, Athens

12462

RECRUITING

"University General Hospital Attikon", Athens

13015

RECRUITING

Marseille University Hospital Center - North Hospital, Marseille

14033

RECRUITING

University Hospital Center Caen, Caen

26504

RECRUITING

University General Hospital of Patras, Pátrai

33612

RECRUITING

H. Lee Moffitt Cancer Center & Research Institute, Tampa

33705

RECRUITING

St. Anthony's Hospital - BayCare Health System, St. Petersburg

35033

RECRUITING

Rennes University Hospital Center - Hospital Pontchaillou, Rennes

45500

RECRUITING

University General Hospital of Ioannina, Ioannina

49333

RECRUITING

Angers University Hospital Center, Angers

53792

RECRUITING

UW Carbone Cancer Center - Cancer Connect, Madison

59037

NOT_YET_RECRUITING

Hospital Calmette, Lille

60637

NOT_YET_RECRUITING

University of Chicago Medical Center, Chicago

69373

RECRUITING

Leon Berard Center, Lyon

76031

RECRUITING

Charles Nicolle Hospital, Rouen

77090

RECRUITING

Millennium Research & Clinical Development, Houston

87042

RECRUITING

CHU de Limoges, Limoges

94805

RECRUITING

Gustave Roussy, Villejuif

H-1121

RECRUITING

Koranyi National Institute of Pulmonology, 14th Department of Pulmonology, Budapest

H-5000

RECRUITING

Jasz-Nagykun-Szolnok County Hetenyi Geza Hospital-Clinic, Department of Oncology, Szolnok

H-2045

NOT_YET_RECRUITING

Pulmonology Institute Torokbalint, Törökbálint

15-540

RECRUITING

University Teaching Hospital in Bialystok, 2nd Department of Lung Diseases and Tuberculosis, Bialystok

31-202

RECRUITING

John Paul II Specialist Hospital in Krakow, Krąków

20-093

RECRUITING

Mandziuk Slawomir - Specialist Medical Practice, Lublin

60-569

RECRUITING

Eugenia and Janusz Zeyland Wielkopolskie Centre of Pulmonology and Thoracic Surgery, Poznan

82-550

RECRUITING

Specialist Hospital in Prabuty Sp. z o.o. (LLC), Prabuty

04-141

RECRUITING

Military Institute of Medicine - National Research Institute, Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Innate Pharma

INDUSTRY

NCT05742607 - IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | Biotech Hunter | Biotech Hunter